Vistin Pharma Asa · OSL:VISTN
Vistin Pharma Asa — Q1 2023 Earnings Presentation
31 slides from Vistin Pharma Asa's earnings presentation, Apr 27, 2023
Slide 1: Q1 2023 presentation, Kjell-Erik Nordby (CEO) / Alexander Karlsen (CFO)
Kjell-Erik Nordby(CEO) / Alexander Karlsen (CFO) 27 April 2023
Slide 2: We believe in balance in life
We believe in balance in life. We want to grow our business but not at the expense of the environment, people’s wellbeing, or sound business principles
Slide 3: Agenda
Agenda Highlights Operational review Financial review MEP & Summary Appendix
Slide 4: First quarter 2023 results highlights
Highlights First quarter 2023 results MNOK 101 in revenue vs. MNOK 33 in Q1 2022 Other • Manufacturing from two production lines in the quarter • Net profit negatively affected with MNOK 15 by fair has resulted in more volumes available for sale, value of FX cash flow hedging contracts (unrealized c
Slide 5: Vistin has high focus on reducing local and global emissions
Vistin has high focus on reducing local and global emissions, and programs are in place to consume responsibly and recycle where possible
Slide 6: Slide 6
Slide 7: Agenda
Agenda Highlights Operational review Financial review MEP & Summary Appendix
Slide 8: We are pure play metformin company with a bright outlook
We are pure play metformin company with a bright outlook A bright outlook Diabetes Metformin for Vistin Pharma One of the largest + The gold standard = A leading global health emergencies treatment of type in the 21st century 2 diabetes producer of premium metformin • Market demand for Metformin is
Slide 9: Vistin Pharma today produce about 10% of the world's demand for Metformin HCl API
Vistin Pharma today produce about 10% of the world’s demand for Metformin HCl API
Slide 10: Metformin: 1st-line treatment
Operational review pharmaceuticals 1st-line treatment Used to lower glucose (blood sugar) levels • Reduces the liver’s production of glucose • Delays and reduces absorption of glucose from the intestine • Increases insulin sensitivity, leading to increased uptake of glucose in the body Most cost-eff
Slide 11: Diabetes – A global emergency
Diabetes – A global emergency
Slide 12: Diabetes – a global epidemic
Diabetes – a global epidemic ■ An estimated 537 million adults aged 20–79 ■ An estimated 537 million adults aged 20–79 years are currently living with years are currently living with diabetes. This diabetes. This represents 10.5% of the world’s population in this age group represents 10.5% of the wo
Slide 13: Vistin Pharma is a metformin player with a world wide sales coverage
Vistin Pharma is a metformin player with a world wide sales coverage
Slide 14: World sales map
World sales map North Atlantle Ocean North South Atlantic ‘Ocean
Slide 15: Slide 15
Slide 16: Agenda
Agenda Highlights Operational review Financial review MEP & Summary Appendix
Slide 17: Production volume continued to increase in Q1
Financial review Production volume continued to increase in Q1, and is expected to continue to increase throughout 2023 Quarterly sales volume metformin (HCl & DC) Quarterly production volume metformin HCl 1400 1400 1240 1200 1200 1200 1145 1112 1061 1031 1025 956 1000 922 933 1000 918 892 900 857 8
Slide 18: Key quarterly figures - revenue
Financial review Key quarterly figures - revenue 120 • Revenue increase of 204% compared to 99 101 Q1’22. Manufacturing from two production 100 92 lines in the quarter has resulted in more volumes available for sale, compared to the 80 78 eight-week production stop in Q1’22 due to the 71 67 69 MEP i
Slide 19: Key quarterly figures - Gross margin %
Financial review Key quarterly figures - Gross margin % 80 % • Gross margin in Q1 positively affected by weaker 68 % 68 % 68 % NOK compared to EUR, partly offset by a stronger 70 % 64 % USD compared to NOK 60 % 57 % • Adjusted for currency (EURNOK & USDNOK) and 54 % mix, the gross margin is 2-3% bet
Slide 20: Key quarterly figures - EBITDA
Financial review Key quarterly figures - EBITDA 20 15 • MNOK 14 in EBITDA vs. MNOK -18 in Q1 2022. 15 13 14 EBITDA positively affected by increased sales 11 10 volume, higher sales prices, competitive energy 10 costs and a weak NOK vs EUR, partly offset by 5 a strong USD vs NOK 5 4 • Q1’22 unfavorab
Slide 21: Key figures: income statement
Financial review Key figures: income statement (NOK 1 000) Q1 2023 Q1 2022 FY 2022 TOTAL REVENUE AND OTHER INCOME TOTAL REVENUE AND OTHER INCOME 100 940 33 219 304 853 EBITDA EBITDA 14 141 (18 194) 6 184 EBT EBT (3 821) (19 424) (6 008) Depreciation & amortisation (4 199) (2 749) (12 280) Net financ
Slide 22: Balance sheet - assets
Financial review Balance sheet Assets 31.03.2023 31.03.2022 31.12.2022 • Deferred tax asset in relation to ASSETS realized loss for Energy Trading in Q1 Non-current assets 2020 Fixed assets 216 648 184 342 219 430 Deferred tax assets 29 270 32 132 28 601 Total non-current assets 245 918 216 474 248
Slide 23: Balance sheet - equity and liabilities
Financial review Balance sheet Equity and liabilities 31.03.2023 31.03.2022 31.12.2022 EQUITY AND LIABILITIES Equity Share capital 44 345 44 345 44 345 • Strong balance sheet with an equity ratio of Share premium 206 885 206 885 206 885 70% Retained earnings 19 055 9 387 22 033 Total equity 270 285
Slide 24: Slide 24
Slide 25: Agenda
Agenda Highlights Operational review Financial review MEP & Summary Appendix
Slide 26: Summary
MEP & Summary Summary Metformin market expected to continue to grow The expansion project to increase the capacity by 5-6% annually to +/-7000MT by year end is progressing • Diabetes is one of the largest health crises of the 21 st century • Metformin is expected to maintain its position as the Gold
Slide 27: Capital Markets Day 14 June
CAPITAL MARKETS DAY 14. juni på FB ALK: Legger inn slide/one-pager fra Skarpsinn før Styremøte
Slide 28: ee ea |
ee ea | q |
Slide 29: Agenda
Agenda Highlights Operational review Financial review MEP & Summary Appendix
Slide 30: Top 20 shareholders as of 31 March 2023
Appendix Top 20 share- NAME SHAREHOLDING % SHARE INTERTRADE SHIPPING AS* 12 575 000 28,36 % HOLMEN SPESIALFOND 3 520 243 7,94 % holders as of PACTUM AS* MP PENSJON PK 3 519 733 1 719 848 7,94 % 3,88 % 1,77 % 31 March 2023 FERNCLIFF LISTED DAI AS* STORKLEIVEN AS AUGUST RINGVOLD AGENTUR AS 784 280 751
Slide 31: Thank you for your attention
Thank you for your attention. www.vistin.com Kjell-Erik Nordby (CEO) Alexander Karlsen (CFO) 27 April 2023